Cargando…
Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory sy...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054127/ https://www.ncbi.nlm.nih.gov/pubmed/33898162 http://dx.doi.org/10.1007/s40629-021-00165-7 |
_version_ | 1783680243546980352 |
---|---|
author | Klimek, Ludger Bergmann, Karl-Christian Brehler, Randolf Pfützner, Wolfgang Zuberbier, Torsten Hartmann, Karin Jakob, Thilo Novak, Natalija Ring, Johannes Merk, Hans Hamelmann, Eckard Ankermann, Tobias Schmidt, Sebastian Untersmayr, Eva Hötzenecker, Wolfram Jensen-Jarolim, Erika Brockow, Knut Mahler, Vera Worm, Margitta |
author_facet | Klimek, Ludger Bergmann, Karl-Christian Brehler, Randolf Pfützner, Wolfgang Zuberbier, Torsten Hartmann, Karin Jakob, Thilo Novak, Natalija Ring, Johannes Merk, Hans Hamelmann, Eckard Ankermann, Tobias Schmidt, Sebastian Untersmayr, Eva Hötzenecker, Wolfram Jensen-Jarolim, Erika Brockow, Knut Mahler, Vera Worm, Margitta |
author_sort | Klimek, Ludger |
collection | PubMed |
description | BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. METHODS: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). RESULTS: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. CONCLUSION: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose. |
format | Online Article Text |
id | pubmed-8054127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-80541272021-04-19 Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI Klimek, Ludger Bergmann, Karl-Christian Brehler, Randolf Pfützner, Wolfgang Zuberbier, Torsten Hartmann, Karin Jakob, Thilo Novak, Natalija Ring, Johannes Merk, Hans Hamelmann, Eckard Ankermann, Tobias Schmidt, Sebastian Untersmayr, Eva Hötzenecker, Wolfram Jensen-Jarolim, Erika Brockow, Knut Mahler, Vera Worm, Margitta Allergo J Int Position Article BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. METHODS: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). RESULTS: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. CONCLUSION: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose. Springer Medizin 2021-04-19 2021 /pmc/articles/PMC8054127/ /pubmed/33898162 http://dx.doi.org/10.1007/s40629-021-00165-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Position Article Klimek, Ludger Bergmann, Karl-Christian Brehler, Randolf Pfützner, Wolfgang Zuberbier, Torsten Hartmann, Karin Jakob, Thilo Novak, Natalija Ring, Johannes Merk, Hans Hamelmann, Eckard Ankermann, Tobias Schmidt, Sebastian Untersmayr, Eva Hötzenecker, Wolfram Jensen-Jarolim, Erika Brockow, Knut Mahler, Vera Worm, Margitta Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI |
title | Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI |
title_full | Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI |
title_fullStr | Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI |
title_full_unstemmed | Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI |
title_short | Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI |
title_sort | practical handling of allergic reactions to covid-19 vaccines: a position paper from german and austrian allergy societies aeda, dgaki, gpa and ögai |
topic | Position Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054127/ https://www.ncbi.nlm.nih.gov/pubmed/33898162 http://dx.doi.org/10.1007/s40629-021-00165-7 |
work_keys_str_mv | AT klimekludger practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT bergmannkarlchristian practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT brehlerrandolf practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT pfutznerwolfgang practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT zuberbiertorsten practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT hartmannkarin practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT jakobthilo practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT novaknatalija practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT ringjohannes practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT merkhans practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT hamelmanneckard practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT ankermanntobias practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT schmidtsebastian practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT untersmayreva practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT hotzeneckerwolfram practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT jensenjarolimerika practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT brockowknut practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT mahlervera practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai AT wormmargitta practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai |